RO Stock Analysis: Roche Holding | SW
Drug Manufacturers - General | SW, Switzerland | Market Cap: 316.635m CHF | 12M Return: 54.4% | CH0012032113 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 10.3M
Warnings
No concerns identified
Tailwinds
Seasonality 11.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Roche Holding AG is a Switzerland-based healthcare company operating globally across pharmaceuticals and diagnostics. Its medicines address conditions including cancer, blood disorders, autoimmune diseases, and neurological disorders; its diagnostics business supplies in vitro tests, instruments, and digital health solutions for diseases such as cancer, diabetes, and hepatitis.
Roche’s integrated business combines drug development with diagnostic products used to detect and monitor disease. Founded in 1896 and headquartered in Basel, the company also collaborates with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors.
- Vabysmo, Hemlibra and newer cancer drugs drive pharma growth
- China pricing reforms and weaker testing demand pressure diagnostics sales
- Patent expiries and pipeline results shape future revenue growth
| Net Income: 12.3b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA 1.75 > 1.0 |
| NWC/Revenue: 10.81% < 20% (prev 17.44%; Δ -6.63% < -1%) |
| CFO/TA 0.19 > 3% & CFO 18.4b > Net Income 12.3b |
| Net Debt (23.6b) to EBITDA (19.9b): 1.18 < 3 |
| Current Ratio: 1.23 > 1.5 & < 3 |
| Outstanding Shares: last quarter (809.3m) vs 12m ago 0.90% < -2% |
| Gross Margin: 72.73% > 18% (prev 73.54%; Δ -0.81% > 0.5%) |
| Asset Turnover: 63.16% > 50% (prev 49.14%; Δ 14.01% > 0%) |
| Interest Coverage Ratio: 11.96 > 6 (EBIT TTM 16.5b / Interest Expense TTM 1.38b) |
| A: 0.07 (Total Current Assets 35.4b - Total Current Liabilities 28.8b) / Total Assets 98.2b |
| B: 0.48 (Retained Earnings 47.5b / Total Assets 98.2b) |
| C: 0.17 (EBIT TTM 16.5b / Avg Total Assets 96.5b) |
| D: 0.53 (Book Value of Equity 32.7b / Total Liabilities 61.5b) |
| Altman-Z'' = 3.73 = AA |
| DSRI: 0.86 (Receivables 13.3b/11.9b, Revenue 60.9b/46.6b) |
| GMI: 1.01 (GM 73.54% / 72.73%) |
| AQI: 1.05 (AQ_t 0.40 / AQ_t-1 0.38) |
| SGI: 1.31 (Revenue 60.9b / 46.6b) |
| TATA: -0.06 (NI 12.3b - CFO 18.4b) / TA 98.2b) |
| Beneish M = -2.89 (Cap -4..+1) = A |
As of November 03, 2026, the stock is trading at CHF 406.60 with a total of 25,292 shares traded. Over the past week, the price has changed by +0.79%, over one month by +14.28%, over three months by +12.94% and over the past year by +54.38%.
Current recommended Stop Loss: 397.10 (which is 2.3% or 1.3 ATR below the current price).
Roche Holding has no consensus analysts rating.
P/E Trailing = 25.923
P/E Forward = 15.9744
P/S = 5.0292
P/B = 8.5933
P/EG = 1.6064
Revenue TTM = 60.9b CHF
EBIT TTM = 16.5b CHF
EBITDA TTM = 19.9b CHF
Long Term Debt = 25.2b CHF (from longTermDebt, last quarter)
Short Term Debt = 6.58b CHF (from shortTermDebt, last quarter)
Debt = 33.4b CHF (from shortLongTermDebtTotal, last quarter) + Leases 1.55b
Net Debt = 23.6b CHF (calculated: Debt 33.4b - CCE 9.73b)
Enterprise Value = 340b CHF (317b + Debt 33.4b - CCE 9.73b)
Interest Coverage Ratio = 11.96 (Ebit TTM 16.5b / Interest Expense TTM 1.38b)
EV/FCF = 23.05x (Enterprise Value 340b / FCF TTM 14.8b)
FCF Yield = 4.34% (FCF TTM 14.8b / Enterprise Value 340b)
FCF Margin = 24.23% (FCF TTM 14.8b / Revenue TTM 60.9b)
Net Margin = 20.25% (Net Income TTM 12.3b / Revenue TTM 60.9b)
Gross Margin = 72.73% ((Revenue TTM 60.9b - Cost of Revenue TTM 16.6b) / Revenue TTM)
Gross Margin QoQ = 73.72% (prev 71.74%)
Tobins Q-Ratio = 3.46 (Enterprise Value 340b / Total Assets 98.2b)
Interest Expense / Debt = 4.15% (Interest Expense 1.38b / Debt 33.4b)
Taxrate = 18.74% (3.07b / 16.4b)
NOPAT = 13.4b (EBIT 16.5b * (1 - 18.74%))
Current Ratio = 1.23 (Total Current Assets 35.4b / Total Current Liabilities 28.8b)
Debt / Equity = 1.02 (Debt 33.4b / totalStockholderEquity, last quarter 32.7b)
Debt / EBITDA = 1.18 (Net Debt 23.6b / EBITDA 19.9b)
Debt / FCF = 1.60 (Net Debt 23.6b / FCF TTM 14.8b)
Total Stockholder Equity = 31.7b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.79% (Net Income 12.3b / Total Assets 98.2b)
RoE = 38.89% (Net Income TTM 12.3b / Total Stockholder Equity 31.7b)
RoCE = 29.05% (EBIT 16.5b / Capital Employed (Equity 31.7b + L.T.Debt 25.2b))
RoIC = 18.45% (NOPAT 13.4b / Invested Capital 72.9b)
WACC = 5.02% (E(317b)/V(350b) * Re(5.19%) + D(33.4b)/V(350b) * Rd(4.15%) * (1-Tc(0.19)))
Discount Rate = 5.19% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 29.72 | Cagr: 0.18%
[DCF] Terminal Value 77.97% ; FCFF base≈13.9b ; Y1≈15.9b ; Y5≈23.4b
[DCF] Fair Price = 3.08k (EV 353b - Net Debt 23.6b = Equity 329b / Shares 106.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -7.72 | EPS CAGR: -5.81% | SUE: 0.0 | # QB: 0
Revenue Correlation: -33.60 | Revenue CAGR: -4.69% | SUE: 1.25 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-09-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=20.44 | Chg30d=+0.42% | Revisions=+25% | GrowthEPS=+5.0% | GrowthRev=+2.9%
EPS next Year (2027-12-31): EPS=22.09 | Chg30d=+0.35% | Revisions=+25% | GrowthEPS=+8.1% | GrowthRev=+4.6%